[Form 4] uniQure N.V. Insider Trading Activity

Rhea-AI Filing Summary

uniQure N.V. insider Matthew C. Kapusta completed option exercises and multiple open-market sales under a 10b5-1 plan on September 24, 2025. The filing shows exercises of stock options at $7.53 (51,316 shares) and $6.22 (175,000 shares), producing reported acquisitions of 226,316 ordinary shares that increased his beneficial holdings to 877,770 shares before subsequent sales. The reporting person sold a series of shares the same day in multiple transactions at weighted-average prices reported between $39.20 and $45.30, resulting in a net decline to 651,454 shares beneficially owned after all reported sales. The transactions were made pursuant to a January 28, 2025 Rule 10b5-1 plan, and the Form 4 was signed by an attorney-in-fact on September 26, 2025.

Positive

• Transactions were executed under a documented Rule 10b5‑1 plan, reducing insider trading timing concerns
• Full disclosure of option vesting and weighted‑average sale price ranges is included in the filing

Negative

• Insider sold a material number of shares, reducing beneficial ownership from 877,770 to 651,454 shares
• Large-scale monetization at current market levels could be viewed negatively by some investors

Insights

Securities Analyst

TL;DR: Insider exercised low‑strike options and executed large, rule‑based sales the same day, materially reducing holdings but following a pre‑arranged plan.

The filing documents exercise of 226,316 option shares at strikes of $6.22 and $7.53 and immediate off‑market sales executed under a 10b5‑1 plan at weighted average prices ranging roughly $39.20–$45.30. This represents a significant monetization of equity accrued at much lower exercise prices and reduces reported beneficial ownership from a high of 877,770 to 651,454 shares. Because the trades were made under a pre‑established 10b5‑1 plan, they appear procedural rather than event‑driven, but the scale of sales is material relative to typical insider activity and could affect short‑term float and market perception.

Corporate Governance Expert

TL;DR: Transactions comply with Rule 10b5‑1 and were disclosed on Form 4; governance procedures appear followed.

The filer discloses the adoption date of the 10b5‑1 plan (January 28, 2025) and includes standard footnotes about weighted average prices and vesting schedules. The presence of an attorney‑in‑fact signature and the detailed explanatory footnotes indicate adherence to disclosure protocols. From a governance perspective, this is routine compliance and transparent reporting of option exercises and scheduled sales, though stakeholders may note the sizeable reduction in insider ownership.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Kapusta Matthew C

(Last) (First) (Middle)

C/O UNIQURE, N.V.

PAASHEUVELWEG 25A

(Street)

AMSTERDAM P7 11058BP

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
uniQure N.V. [ QURE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO, Managing Director

3. Date of Earliest Transaction (Month/Day/Year)
09/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	09/24/2025		M(1)		51,316	A	$7.53	702,770	D
Ordinary Shares	09/24/2025		M(1)		175,000	A	$6.22	877,770	D
Ordinary Shares	09/24/2025		S(1)		51,316	D	$39.59(2)	826,454	D
Ordinary Shares	09/24/2025		S(1)		60,000	D	$40.04(3)	766,454	D
Ordinary Shares	09/24/2025		S(1)		49,978	D	$40.68(4)	716,476	D
Ordinary Shares	09/24/2025		S(1)		5,022	D	$41.69(5)	711,454	D
Ordinary Shares	09/24/2025		S(1)		60,000	D	$45.1(6)	651,454	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$7.53	09/24/2025		M(1)			51,316	(7)	09/29/2026	Ordinary Shares	51,316	$0	0(8)	D
Stock Option (Right to Buy)	$6.22	09/24/2025		M(1)			175,000	(9)	03/14/2027	Ordinary Shares	175,000	$0	0	D

Explanation of Responses:

1. The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on January 28, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.20 to $40.15. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.00 to $40.15. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.42 to $41.42 The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

5. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.56 to $41.76. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

6. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.00 to $45.30. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

7. The Stock Option vested 25% on September 29, 2017 and 6.25% quarterly thereafter.

8. Adjusted to reflect the exercise and sale of 7,501 option shares under the Reporting Person's 10b5-1 plan on February 19, 2020.

9. The Stock Option vested 25% on March 14, 2018 and 6.25% quarterly thereafter.

	/s/ Christian Klemt, Attorney-in-Fact	09/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did uniQure (QURE) insider Matthew Kapusta do on September 24, 2025?

He exercised options for 226,316 shares (at $7.53 and $6.22) and sold multiple tranches of ordinary shares the same day under a 10b5‑1 plan.

How many shares does Kapusta beneficially own after these transactions?

651,454 ordinary shares are reported as beneficially owned following the transactions.

Were the sales part of a pre‑arranged plan?

Yes. The filing states the transactions were effected pursuant to a Rule 10b5‑1 sales plan adopted on January 28, 2025.

At what prices were the shares sold?

Weighted average sale prices are reported with ranges from approximately $39.20 to $45.30 across multiple transactions.

Who signed the Form 4?

The Form 4 was signed by an attorney‑in‑fact, Christian Klemt, on September 26, 2025.